Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 3/20 | 0.35 |
| ▸ | NOS2 | P35228 | 3/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24679533 | 1.00 | DPP4 (0.45) | DPP4SPHK1SPHK2EPHX1CYP1A2 | |
| SCHEMBL2857968 | 0.96 | DPP4 (0.49) | DPP4SPHK1SPHK2EPHX1CYP1A2 | |
| SCHEMBL2447602 | 0.94 | DPP4 (0.47) | DPP4SPHK1SPHK2EPHX1CYP1A2 | |
| SCHEMBL5562923 | 0.94 | DPP4 (0.51) | DPP4SPHK1SPHK2EPHX1CYP1A2 | |
| SCHEMBL2869525 | 0.94 | DPP4 (0.47) | DPP4SPHK1SPHK2EPHX1CYP1A2 | |
| SCHEMBL2448263 | 0.94 | DPP4 (0.47) | DPP4SPHK1SPHK2EPHX1CYP1A2 | |
| SCHEMBL2453079 | 0.94 | DPP4 (0.47) | DPP4SPHK1SPHK2EPHX1CYP1A2 | |
| SCHEMBL2863702 | 0.94 | DPP4 (0.47) | DPP4SPHK1SPHK2EPHX1CYP1A2 | |
| SCHEMBL17662709 | 0.93 | DPP4 (0.50) | DPP4CYP1A2NOS1NOS2CA1 | |
| SCHEMBL2449974 | 0.89 | DPP4 (0.54) | DPP4CYP1A2NOS1NOS2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| US-7186735-B2 | Acylated arylcycloalkylamines and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-06 | — | — | US | disclosed |
| WO-2006102308-A2 | BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-1529031-A1 | ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-11 | — | — | EP | disclosed |
| US-20040082628-A1 | Acylated arylcycloalkylamines and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-04-29 | — | — | US | disclosed |
| WO-2004014842-A1 | ACYLATED ARYLCYCLOALKYLAMINES AND THEIR USE AS PHARMACEUTICALS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-19 | — | — | WO | disclosed |
| EP-1388535-A1 | Acylated arylcycloalkylamines and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082628-A1 | Acylated arylcycloalkylamines and their use as pharmaceuticals | LIPG, AADAC, NAT1 | DPP4 1386/4885SPHK1 723/4885SPHK2 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.